James R. Tobin is listed as a director on 15 SEC Form D filings by 4 issuers between Aug 2011 and Jun 2023: Lyra Therapeutics, Inc. (Watertown, MA — biotechnology — 2022–2023; $100.5M reported sold to 34 investors), TransMedics, Inc. (Andover, MA — other health care — 2011–2016; $63.7M reported sold to 26 investors), Corindus Vascular Robotics, Inc. (Waltham, MA — other health care — 2018–2019; $45M reported sold to 63 investors) and CURIS INC (Lexington, MA — biotechnology — 2012; $964K reported sold to 2 investors).
What this means A repeat sponsor — 4 separate companies raised money with this person listed as director, over about 12 years. Across those companies the filings report $210.2M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 9 bankruptcy cases matching the name listed in Key records below.
What this means 9 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 15 public filings for James R. Tobin and found 9 differences: Form D filed 35 days after the first sale; Offering amount changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.